DE

569.1

+1.6%↑

FDX

362.41

+3.49%↑

CTAS

171.17

+1.56%↑

HEICO

276.63

+1.29%↑

PAYX

91.7

-1.68%↓

DE

569.1

+1.6%↑

FDX

362.41

+3.49%↑

CTAS

171.17

+1.56%↑

HEICO

276.63

+1.29%↑

PAYX

91.7

-1.68%↓

DE

569.1

+1.6%↑

FDX

362.41

+3.49%↑

CTAS

171.17

+1.56%↑

HEICO

276.63

+1.29%↑

PAYX

91.7

-1.68%↓

DE

569.1

+1.6%↑

FDX

362.41

+3.49%↑

CTAS

171.17

+1.56%↑

HEICO

276.63

+1.29%↑

PAYX

91.7

-1.68%↓

DE

569.1

+1.6%↑

FDX

362.41

+3.49%↑

CTAS

171.17

+1.56%↑

HEICO

276.63

+1.29%↑

PAYX

91.7

-1.68%↓

Search

John Wiley & Sons Inc

Abrir

SetorSetor Industrial

0

Visão Geral

Variação de preço das ações

24h

Atual

Mín

Máximo

Indicadores-chave

By Trading Economics

Rendimento

-15M

30M

Vendas

-12M

410M

P/E

Médio do Setor

12.927

57.257

Rendimento de Dividendos

3.92

Margem de lucro

7.238

Funcionários

5,200

EBITDA

-202K

105M

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

3.92%

2.27%

Próximos Ganhos

16 de jun. de 2026

Próxima data de dividendos

23 de abr. de 2026

Próxima data de ex-dividendo

7 de abr. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

294M

1.9B

Abertura anterior

0

Fecho anterior

0

Sentimento de Notícias

By Acuity

50%

50%

187 / 405 Ranking em Industrials

John Wiley & Sons Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

31 de mar. de 2026, 23:31 UTC

Ações em Alta

Stocks to Watch: Nike, RH, NCino

31 de mar. de 2026, 22:35 UTC

Ganhos

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 de abr. de 2026, 00:00 UTC

Aquisições, Fusões, Aquisições de Empresas

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 de mar. de 2026, 23:50 UTC

Aquisições, Fusões, Aquisições de Empresas

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 de mar. de 2026, 23:43 UTC

Conversa de Mercado

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 de mar. de 2026, 23:33 UTC

Conversa de Mercado
Notícias Principais

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 de mar. de 2026, 23:21 UTC

Ganhos

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 de mar. de 2026, 23:14 UTC

Conversa de Mercado
Ganhos

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 de mar. de 2026, 23:12 UTC

Conversa de Mercado

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss Widens >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 de mar. de 2026, 22:36 UTC

Ganhos

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 de mar. de 2026, 21:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 de mar. de 2026, 21:36 UTC

Conversa de Mercado

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 de mar. de 2026, 21:35 UTC

Ganhos

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 de mar. de 2026, 21:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 de mar. de 2026, 21:33 UTC

Ganhos

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 de mar. de 2026, 21:32 UTC

Ganhos

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 de mar. de 2026, 21:28 UTC

Ganhos

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 de mar. de 2026, 21:26 UTC

Ganhos

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 de mar. de 2026, 21:25 UTC

Ganhos

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 de mar. de 2026, 21:24 UTC

Conversa de Mercado
Ganhos

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 de mar. de 2026, 21:22 UTC

Ganhos

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 de mar. de 2026, 21:21 UTC

Ganhos

Nike's Digital Channel Still Too Promotional, CFO Says

31 de mar. de 2026, 21:20 UTC

Ganhos

Nike CEO: Converse Remains Important to Portfolio

Comparação entre Pares

Variação de preço

John Wiley & Sons Inc Previsão

Consenso de Avaliação

By TipRanks

0 ratings

0

Comprar

0

Manter

0

Vender

Sentimento

By Acuity

187 / 405 Ranking em Setor Industrial

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre John Wiley & Sons Inc

John Wiley & Sons, Inc. operates as a research and learning company worldwide. It operates through three segments: Research, Learning, and Held for Sale or Sold. The company offers scientific, technical, medical, and scholarly journals, as well as related content and services to learned societies, individual researchers, other professionals, as well as academic, corporate, and government libraries. It publishes physical sciences and engineering, health sciences, social sciences, and humanities and life sciences journals through research libraries and library consortia, and independent subscription agents, direct to professional society members, and other customers ; and operates Literatum, an online publishing platform for production and content hosting, submissions and peer review support, editorial, and copyediting services. The company also offers academic and professional products and services, including scientific, professional, education print and digital books, and digital courseware to libraries, corporations, students, professionals, and researchers through chain and online booksellers, libraries, colleges and universities, corporations, direct to consumer, websites, distributor networks, and other online applications. In addition, it provides learning, development, publishing, and assessment services to businesses and professionals; and online learning and training solutions for global corporations and small and medium-sized enterprises. John Wiley & Sons, Inc. was formerly known as John Wiley And Sons and changed its name to John Wiley & Sons, Inc. in November 1953. The company was founded in 1807 and is based in Hoboken, New Jersey.
help-icon Live chat